IOLCPIOL CHEMICALS & PHARMACEUTICALS LTD.
IOL Chemicals: consolidated PAT surges 90% YoY to ₹64.4 Cr as revenue jumps 37%, OPM expands
pharma api · chemical segment · margin expansion
Research Reports
10 Aug 2026
ASTRAZENASTRAZENECA PHARMA INDIA LTD.
AstraZeneca India Q1 standalone PAT falls 32% YoY to ₹37.9 Cr as margins compress
pharma · margin compression · pat decline
SPARCSUN PHARMA ADVANCED RESEARCH COMPANY LTD.
SPARC Q1 loss narrows to ₹20.8 Cr YoY, but the gain is a one-off licensing fee
pharma r&d · one-off revenue · licensing termination
LYKALABSLYKA LABS LTD.
Lyka Labs Q1 FY27: consolidated PAT doubles YoY to ₹2.05 Cr as revenue rises 28%
pharmaceuticals · subsidiary divestment · revenue growth
KPLKwality Pharmaceuticals Ltd
Kwality Pharma Q1FY27: consolidated PAT surges 115% YoY to ₹25.6 Cr, margins expand, guidance raised
pharma exports · margin expansion · guidance raise
GLANDGland Pharma Ltd
Gland Pharma's $90–100M CDMO Prize: When a Pharma Contract Becomes a Business
CDMO · sterile injectables · contract manufacturing
ResearchDeep dive5 minPharma & Healthcare
CAPLIPOINTCAPLIN POINT LABORATORIES LTD.
Sterile Upside: US Momentum Meets Core Growth
Q1 FY27 · sterile injectables · US generics
JUBLPHARMAJubilant Pharmova Ltd
CDMO Momentum vs. Quality Headwinds — What to Expect on Aug 10
CDMO · sterile injectables · USFDA warning letter
09 Aug 2026
SPARCSUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Back to reality: SPARC reports without the $195M PRV windfall
SPARC · earnings preview · R&D biotech
ASTRAZENASTRAZENECA PHARMA INDIA LTD.
Enhertu Ramp & Pricing Headwinds: The Q1 Balancing Act
ASTRAZEN · pharma · earnings preview
RUBICONRubicon Research Ltd
Growth levers engaged: Q1 FY27 shapes up as inflection on acquisitions and capacity build
pharma earnings · M&A integration · FDA compliance
08 Aug 2026
LALPATHLABDr. Lal PathLabs Ltd
Dr. Lal's Handoff: When the Founder Steps Back, ESOP Keeps the Faith
ESOP · founder succession · diagnostics
ResearchDeep dive6 minPharma & Healthcare
AMANTAAmanta Healthcare Ltd
Revenue on track, profit delayed — overhead absorption masks the Q1 story
SteriPort · capacity-delay · overhead-absorption
AMANTAAmanta Healthcare Ltd
SteriPort delays weigh Q1; strong multi-year visibility
capacity-delay · polymer-absorption · FY28-targets
AKUMSAkums Drugs and Pharmaceuticals Ltd
Akums Q1FY27: consolidated PAT surges 56% YoY to ₹101 Cr as margins expand, exports miss
cdmo growth · margin expansion · api losses narrowing
PARKHOSPSPark Medi World Ltd
Steady execution amid capacity dilution; long-term roadmap raised
acquisition integration · occupancy recovery · CGHS benefit
NATCOPHARMNATCO PHARMA LTD.
NATCO Pharma Q1 FY27: The Trough Year Begins—Revlimid Cliff and Specialty Ramp
NATCO Pharma · Revlimid cliff · trough year
IPCALABIPCA LABORATORIES LTD.
Sustaining double-digit growth through a transformative year
IPCA · pharma · Q1 results
ALKEMAlkem Laboratories Ltd
Mid-year tracking: margin defense amid FDA headwinds
pharma · generics · US exports
07 Aug 2026
AARTIPHARMAarti Pharmalabs Ltd
Aarti Pharmalabs Q1FY27: consolidated PAT +65% YoY to ₹76 Cr as OPM expands to 25.4%
cdmo growth · margin expansion · capex approval
JSLLJeena Sikho Lifecare Ltd
Jeena Sikho Q1 FY27: PAT +29% YoY on consolidated basis, but core margin slips 416bps
ayurveda healthcare · product segment growth · operating margin compression
KOVAIKOVAI MEDICAL CENTER & HOSPITAL LTD.
Kovai Medical Q1 FY27: standalone PAT +21% YoY to ₹69 Cr as margins expand
hospital services · margin expansion · healthcare segment
ENTEROEntero Healthcare Solutions Ltd
Entero Healthcare Q1FY27: consolidated PAT +72% YoY to ₹52 Cr, OPM hits 5% target
pharma distribution · margin expansion · acquisition led growth
ANUHPHRANUH PHARMA LTD.
Anuh Pharma Q1FY27: PAT jumps 38% YoY on margin expansion, revenue growth tepid at 4%
pharma · bulk drugs · margin expansion
HEALTHXSastasundar Ventures Ltd
Health X Platform: revenue jumps 50% YoY but consolidated PAT crashes 93% to ₹2 Cr
healthcare network · margin compression · segment loss
CONCORDBIOConcord Biotech Ltd
Strong 26% growth, margin expansion; long-term bets ramping slower than guided
export momentum 46% · pricing power · injectable facility 5% util.
GUJTHEMGUJARAT THEMIS BIOSYN LTD.
Gujarat Themis Biosyn Q1 FY27: consolidated PAT up 22% YoY to ₹11.07 Cr as OPM expands 870bps
pharma intermediates · api manufacturing · margin expansion
ABBOTINDIAABBOTT INDIA LTD.
Chronic therapies to anchor steady growth; margin resilience key watch
Abbott India · pharma · Q1 FY27
ZYDUSLIFEZydus Lifesciences Ltd
Margin Headwinds Test the Guidance — Zydus Q1 in Focus
earnings preview · Q1 FY27 · Zydus Lifesciences
APOLLOHOSPAPOLLO HOSPITALS ENTERPRISE LTD.
Demerger catalyst and hospital biz acceleration into focus
hospital · demerger · occupancy